ECM
AKTX

Endurant Capital Management’s Akari Therapeutics AKTX Stock Holding History

Endurant Capital Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-258
Closed -$382K – 62
2020
Q4 		$382K Buy
+258
New +$357K 0.14% 50
2018
Q4 		– Sell
-205
Closed -$419K – 53
2018
Q3 		$419K Sell
205
-20
-9% -$32.3K 0.19% 67
2018
Q2 		$352K Sell
225
-22
-9% -$34.6K 0.15% 59
2018
Q1 		$359K Sell
247
-4
-2% -$8.64K 0.13% 68
2017
Q4 		$871K Buy
+251
New +$968K 0.27% 62

Other funds holding AKTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Endurant Capital Management's AKTX Position: Q1 2021 in Review

Endurant Capital Management sold out of Akari Therapeutics (AKTX) in Q1 2021, closing a stake of 258 shares — an estimated $382K sold.

Endurant Capital Management first reported a position in AKTX in Q4 2017 and held it in 5 quarters. The position peaked at $871K in Q4 2017. 12 funds tracked by Wall St. Rank hold AKTX as of Q1 2021.

  • Endurant Capital Management reported no remaining Akari Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Endurant Capital Management sold 258 Akari Therapeutics shares in Q1 2021, an estimated $382K.
  • Endurant Capital Management first reported a position in Akari Therapeutics in Q4 2017 and held it in 5 quarters.
  • Endurant Capital Management's Akari Therapeutics position peaked at $871K in Q4 2017.
  • 12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2021.

Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.